Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,632 shares of the medical research company’s stock after buying an additional 100 shares during the period. Brown Miller Wealth Management LLC’s holdings in Amgen were worth $1,910,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Briaud Financial Planning Inc purchased a new position in shares of Amgen during the third quarter valued at $26,000. OFI Invest Asset Management bought a new stake in Amgen in the third quarter worth approximately $26,000. Planned Solutions Inc. bought a new stake in Amgen in the fourth quarter worth $30,000. Providence Capital Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter worth about $30,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of Amgen in the first quarter worth $28,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.7 %

AMGN traded down $1.98 during mid-day trading on Thursday, hitting $284.32. The stock had a trading volume of 2,288,855 shares, compared to its average volume of 3,040,904. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The firm has a market capitalization of $152.37 billion, a price-to-earnings ratio of 22.81, a price-to-earnings-growth ratio of 2.66 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock’s fifty day simple moving average is $290.09 and its 200-day simple moving average is $280.70.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter last year, the firm posted $4.09 earnings per share. Amgen’s revenue was up 19.8% compared to the same quarter last year. As a group, research analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.17%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. Raymond James started coverage on Amgen in a research report on Thursday. They issued a “market perform” rating for the company. Finally, UBS Group cut their target price on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.